MindMaze Therapeutics Holding SA (RLFTF)

MindMaze Therapeutics Holding SA, listed on OTC Markets under RLFT.F, is identified in the supplied classification as common equity. The source description refers to Relief Therapeutics Holding SA, which was acquired by NeuroX Group SA in a reverse merger transaction as of December 15, 2025. The company had operated as a biopharmaceutical business focused on identifying, developing, and commercializing patented products for rare dermatological, metabolic, and pulmonary diseases. Its portfolio included SETOFILM/ONDISSOLVE for nausea and vomiting linked to radiotherapy, chemotherapy, and postoperative recovery; ACER-001 for urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also developed RLF-100, RLF-TD011, and RLF-OD32 for additional rare disease and respiratory indications. The company was founded in 2013 and is based in Geneva, Switzerland, with operations in Switzerland, Europe, North America, and other international markets.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.